AGIOS PHARMACEUTICALS INC (AGIO)
Health Care · Biotechnology · NASDAQ
Agios Pharmaceuticals is a rare disease-focused biopharmaceutical company advancing a pipeline of novel hematology and genetic disorder therapies, anchored by its pyruvate kinase activator, mitapivat.
What AGIOS PHARMACEUTICALS INC does
Agios Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines for rare genetic diseases, particularly hematologic disorders. Its lead product, mitapivat, is a pyruvate kinase activator marketed under the brands AQVESME and PYRUKYND for the treatment of hemolytic anemias, including PK deficiency and thalassemia. The company is actively expanding its pipeline with treatments for sickle cell disease, phenylketonuria, polycythemia vera, and immune thrombocytopenia.
Themes: rare diseases, hematology, sickle cell disease, gene regulation / siRNA, autoimmune diseases
Fundamentals
- Price$31.92 as of 2026-10-08 close
- Market cap$1.9B as of 2026-07-24 (share count; price 2026-10-08)
- 1-year return-25.1% 2025-10-08 close $42.60 → 2026-10-08 close $31.92
- P/En/a negative earnings
- Net margin-764.0% FY2025, SEC XBRL
- ROE-34.6% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Revenue growth (YoY)+140.6% as of 2026-09-03
- Revenue CAGR (3y)+56.0% SEC XBRL
- Beta1.02 as of 2026-09-03
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
How AGIO compares in its sector
- net profit marginbottom 25% 430 covered Health Care peers, as of 2026-09-03
- operating marginbottom 25% 417 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
AGIO is not currently in any published Top 10 list. Its scores are below.
Top 10 score
51.4 #673 of 1,399 scored · #85 of 152 in Health Care
Growth 98th (revenue growth year over year 140.6%, 3-year revenue CAGR 56%) and valuation 71st (price to book 2); weakest is profitability (3rd, operating margin -873.9%, return on equity -34.6%).
Scores as of 23 Sep 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4. AGIO was not in the scored universe at the latest run on 8 Oct 2026, so these scores are its last ones.
How AGIOS PHARMACEUTICALS INC looks technically
AGIOS PHARMACEUTICALS INC (AGIO) is trading 2.6% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 61 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 11, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 42, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 10 trading days ago (its momentum flipped negative). It made a new 20-day low about 4 trading days ago. It is 30.6% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 2.6% above its 200-day average, the long-term trend line — a longer-term uptrend | +2.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $33.08 | $33.08 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $31.10 | $31.10 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 32.22. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible downward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 61 trading days ago — a "golden cross", a bullish long-term signal | 61 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 11, below the 25 that marks a real trend) | 10.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 42, neither overbought (above 70) nor oversold (below 30) | 42.5 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($30.78 to $35.36) — its "stochastic" reading is 25 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 24.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 10 trading days ago (its momentum flipped negative) | 10 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $45.99 | $45.99 |
|---|---|---|
| From the 52-week high | it is 30.6% below its 52-week high (its highest price of the past year) | -30.6% |
| Above the 52-week low | it is 43.5% above its 52-week low (its lowest price of the past year) | +43.5% |
| Below the 52-week high | it is 30.6% below its highest point of the past year | 30.6% |
| Since a 20-day breakout | it made a new 20-day low about 4 trading days ago | 4 sessions |
| Since a 55-day breakout | it is trading within its recent 55-day range, with no fresh breakout up or down | 0 sessions |
| All-time high | its highest closing price on record is $138.85 (set on 2015-01-15) | $138.85 |
| Given back of the 52-week move | over the past year its closes ranged ($22.34 to $45.49), and it has recovered roughly a third of its fall from last year’s high — 41% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $36.65 to $37.39. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. Worth noting that the whole move happened in 1 day, so it is a narrow thing to be measuring a retracement against. | 41.4% |
| From the all-time high | it is 77.0% below its all-time high | -77.0% |
| Nearest price level | it is trading 1.4% above a support level at $31.49 — a price it turned at five times since 2025-01-02, most recently on 2026-09-24. Since 2024-10-08 it has 9 such levels below the current price and 7 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.4% |
| All-time low | its lowest closing price on record is $15.77 (set on 2013-11-18) | $15.77 |
| Above the all-time low | it is 102.4% above its all-time low | +102.4% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 73% of it) | 27th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.28 between its high and its low — about 4.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.28 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $31.12 and $34.76 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $31.12 – $32.94 – $34.76 |
| Typical daily range (% of price) | its price moves about 4.0% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.0% |
| Stretch from the 200-day average | it is trading 0.6 daily ranges above its 200-day average price (2.6% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.6 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.65× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.5% since the prior reading | -0.5% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bullish engulfing | 8 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 8 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-08 1.0% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.0% |
|---|---|---|
| Open gap | it gapped 10.7% below the previous close 56 sessions ago and has not traded back through the level it left behind at 40.06 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -10.7% |
| Gap filled | a 2.9% gap up opened on 2026-08-19 has been "filled" 34 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 34 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 3 sessions in a row, a +2.14% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 3 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 5.9 percentage points (the stock lost 4.9% while the market gained 1.0%) | -5.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 29.2 percentage points (the stock lost 25.4% while the market gained 3.8%) | -29.2% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 25.7 percentage points (the stock lost 8.3% while the market gained 17.5%) | -25.7% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 40.0 percentage points (the stock lost 25.1% while the market gained 15.0%) | -40.0% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 5.0% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 9.4% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -5.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 1% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $31.57 — a volume-weighted average of daily closes over 191 sessions, not a true tick-by-tick VWAP. | +1.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% below the average price paid since it last reported on 2026-07-30 (its 10-Q), so the typical buyer over that stretch is under water. That average is $32.97 — a volume-weighted average of daily closes over 50 sessions, not a true tick-by-tick VWAP. | -3.2% |
Double top, bearish — broke down · entry $32.64 · 35 sessions in
Price levels it has turned at before
AGIO last closed at $31.92 on 2026-10-08. Since 2024-10-08 it has turned at 9 prices below its last close and 7 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $31.49 | Support | 1.4% below the last close | turned there five times · 2025-01-02 to 2026-09-24 |
| $32.57 | Resistance | 2.0% above the last close | turned there six times · 2025-03-21 to 2026-09-15 |
| $30.73 | Support | 3.7% below the last close | turned there three times · 2025-03-17 to 2026-05-28 |
| $29.98 | Support | 6.1% below the last close | turned there twice · 2025-12-24 to 2026-01-27 |
| $35.63 | Resistance | 11.6% above the last close | turned there 7 times · 2025-01-08 to 2026-09-22 |
| $36.33 | Resistance | 13.8% above the last close | turned there four times · 2025-02-24 to 2026-03-31 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $32.22.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $32.22 and $32.31 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close below $31.37.
This reading has stood for 5 trading days, since 2026-10-02.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · trendless / choppy (low ADX) · lagging the market · Trading at this year’s average price paid (anchored VWAP) · Under water since its last earnings report (below the anchored VWAP) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.60 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$46.00 range $32.00 – $73.00; median $43.50
Analyst estimates, as of 2026-10-08. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for AGIO
- Consensus EPS estimate-$1.20 next reporting period, as of 2026-10-08
- Estimate change, 30 days-$0.0075 from -$1.19, on 2026-09-07, 31-day window
- Readings revised upward11% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on the commercial success of mitapivat and its ability to secure additional regulatory approvals, particularly in sickle cell disease.","Inherent risks of clinical trial failures, regulatory delays, or failure to demonstrate clinical benefit for new indications.","Substantial history of losses and potential need for additional capital to fund research, development, and commercial operations."]
What changed in the latest 10-Q
AI-assisted comparison of AGIO's 10-Q filed 2026-07-30 against the prior one filed 2026-04-29.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-07-30) states that an sNDA for U.S. accelerated approval of mitapivat in sickle cell disease was submitted in May 2026, accepted with priority review by the FDA, and granted a PDUFA goal date of November 1, 2026.
- Newer filing (2026-07-30) states that the REIGNITE phase 3 confirmatory trial was initiated to support the accelerated approval pathway for mitapivat in SCD in patients aged 12 years or older.
- Newer filing (2026-07-30) states that in the second quarter of 2026 Agios filed for regulatory approval for SCD in the Kingdom of Saudi Arabia.
- Newer filing (2026-07-30) adds cevidoplenib, an oral SYK inhibitor in-licensed from Oscotec Inc., to the list of product candidates being developed, for the potential treatment of ITP and other autoimmune indications.
- Newer filing (2026-07-30) adds an 'Oscotec License Agreement' section stating that on June 1, 2026 Agios entered into a license agreement with Oscotec for worldwide rights to cevidoplenib, with Oscotec retaining an opt-in right for South Korea.
- Newer filing (2026-07-30) states that Agios made an up-front payment to Oscotec and recognized in-process research and development of $25.0 million in the three months ended June 30, 2026, recorded in R&D expense and classified as investing activities.
- Newer filing (2026-07-30) states that Agios is responsible to pay up to $140.0 million in potential development and regulatory milestones in the U.S. and Europe, plus sales milestones and tiered royalties on future net sales of licensed products, subject to specified reductions and offsets.
- Newer filing (2026-07-30) includes a 'Financial Operations Overview - General' section heading in the MD&A.
- Removed:
- Older filing (2026-04-29) states that in December 2024 Agios submitted an MAA to the EMA for PYRUKYND for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia.
- Older filing (2026-04-29) states that in October 2025 the CHMP of the EMA adopted a positive opinion for the new PYRUKYND indication in adults for anemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia, with the European Commission final decision expected in the first half of 2026.
- Older filing (2026-04-29) states that in the first quarter of 2026 Agios presented data from the phase 2 and phase 3 portions of the RISE UP study of PYRUKYND in adults with SCD in a pre-sNDA meeting with the FDA.
- Older filing (2026-04-29) states that based on the FDA's recommendation, Agios submitted a proposal for a confirmatory clinical trial to support U.S. accelerated approval of mitapivat in SCD, incorporating a primary endpoint different from the RISE UP study endpoints.
- Older filing (2026-04-29) states that Agios intended to submit an sNDA for mitapivat for SCD in the second quarter of 2026.
- Older filing (2026-04-29) states that Agios was evaluating mitapivat for the treatment of pediatric patients with PK deficiency.
- Older filing (2026-04-29) includes tebapivat, a novel PK activator, for the potential treatment of LR MDS and SCD, in the list of product candidates being developed.
- Older filing (2026-04-29) includes the details of the Retained Earn-Out Rights: Royalty Pharma having rights to a 12% earn-out on excess U.S. net sales over $1.0 billion and Agios retaining the rights to a 3% earn-out, with royalty income recognized when realizable.
- Reworded:
- Newer filing (2026-07-30) changes the description of mitapivat approvals: it now states mitapivat is approved under AQVESME in the U.S. for anemia in adults with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia, and under PYRUKYND in the U.S. for PK deficiency, in the EU for PK deficiency and for non-transfusion dependent and transfusion dependent alpha- or beta-thalassemia in adult patients, in the Kingdom of Saudi Arabia for adults with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia, in the United Arab Emirates for non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia in adult patients, and in Great Britain for PK deficiency in adult patients.
- Older filing (2026-04-29) describes mitapivat approvals differently: approved in the U.S. under AQVESME for anemia in adults with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia; approved under PYRUKYND in Saudi Arabia and the UAE for adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia; approved under PYRUKYND in the U.S. for hemolytic anemia in adults with PK deficiency; and approved in the EU and Great Britain for PK deficiency in adults.
- Newer filing (2026-07-30) removes the EMA/CHMP review update for the EU thalassemia indication that was present in the older filing, and instead reflects the EU approval as already granted in its approval description.
- Notes:
- The newer filing text is truncated mid-sentence at the end of the 'Sale of Oncology Business' section, so changes after that point cannot be assessed.
- The older filing text is truncated at 'Financial Operations Overview - General', so the comparison covers only the portions of the MD&A included in the provided excerpts.
Risk Factors
- Added:
- Newer filing (2026-07-30) states net product revenues of $65.5 million and $21.2 million from sales of PYRUKYND and AQVESME in the six months ended June 30, 2026 and 2025, respectively.
- Removed:
- Older filing (2026-04-29) stated net product revenues of $20.7 million and $8.7 million from sales of PYRUKYND and AQVESME in the three months ended March 31, 2026 and 2025, respectively.
- Reworded:
- Newer filing (2026-07-30) states 'the potential approval of mitapivat for the treatment of SCD in the United States and in other jurisdictions'; older filing (2026-04-29) stated 'the potential approval of mitapivat for the treatment of thalassemia in the EU, or SCD in the United States and in other jurisdictions'.
- Newer filing (2026-07-30) refers to 'our most advanced clinical programs' without naming tebapivat; older filing (2026-04-29) referred to 'our most advanced clinical programs, including mitapivat and tebapivat'.
- Newer filing (2026-07-30) states 'We cannot be certain that we will obtain marketing approval of mitapivat for SCD in the United States or in other jurisdictions, nor can we be certain that we will obtain marketing approval of any other product candidate for any other indication.'; older filing (2026-04-29) stated 'We cannot be certain that we will obtain marketing approval of mitapivat in jurisdictions with pending or potential future marketing applications for thalassemia, nor can we be certain that we will obtain marketing approval of mitapivat for SCD or for any other indication.'
- Notes:
- The provided excerpts may be truncated; only the visible portions of the two texts were compared.
- The newer filing contains a page break indicator '28' and 'Table of Contents' within the excerpt, which does not reflect a substantive change.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 1 sell ($914400) — 1 selling insider
- Last 180 days · read to 2026-10-040 buys · 2 sells ($1M) — 1 selling insider
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-04. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about AGIO's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 5 matched disclosures for AGIO from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
4 institutional 13F filers reported holding AGIO as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 11,855,076
- Reported value $439,953,724
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about AGIO's institutional holders → See what each manager we track holds →
Short interest (FINRA)
AGIO had 7,557,252 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
AGIO had 12.7% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.46 days to cover at the same settlement.
- Reported short interest (shares) 7,557,252
- Short interest (% of shares outstanding) 12.7%
- Prior settlement (shares) 7,535,054
- Reported change 0.29%
- Days to cover (reported) 9.46
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Bluebird Bio (BLUE)
- Vertex Pharmaceuticals (VRTX)
- Bristol Myers Squibb (BMY)
- Novartis (NVS)
- BioMarin Pharmaceutical (BMRN)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AGIO vs…
AGIOS PHARMACEUTICALS INC is found in…
Frequently asked questions
What does AGIOS PHARMACEUTICALS INC (AGIO) do?
Agios Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines for rare genetic diseases, particularly hematologic disorders. Its lead product, mitapivat, is a pyruvate kinase activator marketed under the brands AQVESME and PYRUKYND for the treatment of hemolytic anemias, including PK deficiency and thalassemia.
What sector is AGIOS PHARMACEUTICALS INC (AGIO) in?
AGIOS PHARMACEUTICALS INC (AGIO) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are AGIOS PHARMACEUTICALS INC's (AGIO) competitors?
Notable peers of AGIOS PHARMACEUTICALS INC (AGIO) include Bluebird Bio, Vertex Pharmaceuticals, Bristol Myers Squibb, Novartis and BioMarin Pharmaceutical. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in AGIO?
Yes — we hold 5 matched STOCK Act disclosures for AGIO from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is AGIOS PHARMACEUTICALS INC (AGIO) overbought or oversold right now?
AGIOS PHARMACEUTICALS INC (AGIO) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 42, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AGIO come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.